Secukinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL17A |
| Clinical data | |
| Trade names | Cosentyx |
| Other names | AIN457 |
| AHFS/Drugs.com | cosentyx |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6584H10134N1754O2042S44 |
| Molar mass | 147.94 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Secukinumab, trade name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is manufactured by Novartis Pharma AG for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning.[1] On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.[2] On January 15, 2016, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with ankylosing spondylitis, and psoriatic arthritis.[3]
Medical uses
Contraindications
Adverse effects
Interactions
Pharmacology
Chemistry
History
Society and culture
Research
References
- ^ "Statement On A Non-proprietary Name Adopted By The USAN Council: Secukinumab" (PDF). American Medical Association.
- ^ "FDA approves new psoriasis drug Cosentyx" (Press release). United States Food and Drug Administration. January 21, 2015. Retrieved January 21, 2015.
- ^ "Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US | Novartis". Novartis. 2016-01-15. Retrieved 2017-02-22.
{{cite web}}: Cite has empty unknown parameter:|dead-url=(help)